Nanoparticle compositions of antibacterial compounds and other uses thereof
The present disclosure relates to the development of antibacterial compounds and their nanoparticle compositions. Methods of making the compounds and their nanoparticle compositions, their use as medicament for the treatment of bacterial infection and also for suppressing potentially harmful inflammation are disclosed.
1. A compound of Formula I:
wherein,
‘m’ is an integer ranging from 0 to 1,
‘L’ is an integer ranging from 1 to 100,
R 1 , R 2 and R 3 are, independently at each occurrence, a hydrogen atom or methyl radical or
C 2 -C 40 aliphatic radical or C 3 -C 40 aromatic radical or any combination thereof, and
X ⊖ is selected from a group consisting of chloride, bromide and iodide;
and wherein at least one of R 1 , R 2 , or R 3 comprises a structural moiety selected from a group consisting of:
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3,
and
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3.
2. The compound of claim 1 for use in the treatment of a bacterial infection.
3. The compound of claim 2 , wherein the bacterial infection caused by a Gram-positive bacterium or a Gram-negative bacterium.
4. The compound of claim 1 for use in the treatment of a bacterial infection wherein the bacterial infection caused by a drug-resistant bacterium.
5. The compound of claim 1 for use in the treatment of sepsis.
6. A composition comprising the compound of Formula I
wherein,
‘m’ is an integer ranging from 0 to 1,
‘L’ is an integer ranging from 1 to 100,
R 1 , R 2 and R 3 are, independently at each occurrence, a hydrogen atom or methyl radical or
C 2 -C 40 aliphatic radical or C 3 -C 40 aromatic radical or any combination thereof, and
X ⊖ is selected from a group consisting of chloride, bromide and iodide;
and wherein at least one of R 1 , R 2 , or R 3 comprises a structural moiety selected from a group consisting of:
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and n is an integer ranging from 1 to 4,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3,
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3,
and
wherein, P is a C 1 -C 24 aliphatic saturated radical or a C 2 -C 24 aliphatic unsaturated radical, and y is an integer ranging from 0 to 3.
7. A method of treatment of a bacterial infection in a subject comprising: administering to the subject an effective amount of the composition of claim 6 .
8. The method of claim 7 wherein the bacterial infection is caused by a Gram-positive bacterium or a Gram-negative bacterium.
9. The method of claim 7 , wherein the bacterial infection is caused by a drug-resistant bacterium.
10. The method of claim 7 , wherein the bacterial infection is caused by Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterococcus faecium , methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus faecium or a combination thereof.
11. A method of suppressing inflammation comprising administering to a subject suffering from sepsis the composition of claim 6 .
12. An article comprising the composition of claim 6 .
13. The composition of claim 6 , wherein the composition is a nanoparticle composition.
14. A method of preparing the nanoparticle composition of claim 13 , said method comprising dispersing the compound of Formula I in a solvent system comprising a hydrophilic solvent, a hydrophobic solvent, or a mixture of both.
15. A method of treatment of a bacterial infection in a subject comprising: administering to the subject an effective amount of the nanoparticle composition of claim 13 .
16. The method of claim 15 wherein the bacterial infection is caused by a Gram-positive bacterium or a Gram-negative bacterium.
17. The method of claim 15 , wherein the bacterial infection is caused by a drug-resistant bacterium.
18. The method of claim 15 , wherein the bacterial infection is caused by Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterococcus faecium , methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus faecium or a combination thereof.
19. A method of suppressing inflammation comprising administering to a subject suffering from sepsis the nanoparticle composition of claim 13 .
20. An article comprising the nanoparticle composition of claim 13 .